BIOVENTUS INC - A (BVS) Stock Fundamental Analysis

NASDAQ:BVS • US09075A1088

8.78 USD
-0.08 (-0.9%)
At close: Feb 27, 2026
8.78 USD
0 (0%)
After Hours: 2/27/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

Taking everything into account, BVS scores 5 out of 10 in our fundamental rating. BVS was compared to 184 industry peers in the Health Care Equipment & Supplies industry. There are concerns on the financial health of BVS while its profitability can be described as average. BVS may be a bit undervalued, certainly considering the very reasonable score on growth


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • BVS had positive earnings in the past year.
  • BVS had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: BVS reported negative net income in multiple years.
  • BVS had a positive operating cash flow in 4 of the past 5 years.
BVS Yearly Net Income VS EBIT VS OCF VS FCFBVS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M -150M

1.2 Ratios

  • With a decent Return On Assets value of 1.11%, BVS is doing good in the industry, outperforming 73.91% of the companies in the same industry.
  • With a decent Return On Equity value of 4.71%, BVS is doing good in the industry, outperforming 76.63% of the companies in the same industry.
  • The Return On Invested Capital of BVS (6.62%) is better than 80.43% of its industry peers.
Industry RankSector Rank
ROA 1.11%
ROE 4.71%
ROIC 6.62%
ROA(3y)-11.81%
ROA(5y)-6.59%
ROE(3y)-54.27%
ROE(5y)-31.1%
ROIC(3y)N/A
ROIC(5y)N/A
BVS Yearly ROA, ROE, ROICBVS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

  • BVS has a Profit Margin of 1.39%. This is in the better half of the industry: BVS outperforms 73.37% of its industry peers.
  • The Operating Margin of BVS (8.03%) is better than 75.00% of its industry peers.
  • BVS's Operating Margin has declined in the last couple of years.
  • The Gross Margin of BVS (67.76%) is better than 73.37% of its industry peers.
  • BVS's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 8.03%
PM (TTM) 1.39%
GM 67.76%
OM growth 3Y-2.88%
OM growth 5Y-14.52%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.21%
GM growth 5Y-1.56%
BVS Yearly Profit, Operating, Gross MarginsBVS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BVS is destroying value.
  • BVS has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for BVS has been increased compared to 5 years ago.
  • Compared to 1 year ago, BVS has an improved debt to assets ratio.
BVS Yearly Shares OutstandingBVS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
BVS Yearly Total Debt VS Total AssetsBVS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • Based on the Altman-Z score of 1.34, we must say that BVS is in the distress zone and has some risk of bankruptcy.
  • BVS's Altman-Z score of 1.34 is in line compared to the rest of the industry. BVS outperforms 54.35% of its industry peers.
  • The Debt to FCF ratio of BVS is 6.22, which is on the high side as it means it would take BVS, 6.22 years of fcf income to pay off all of its debts.
  • BVS has a better Debt to FCF ratio (6.22) than 76.63% of its industry peers.
  • BVS has a Debt/Equity ratio of 1.93. This is a high value indicating a heavy dependency on external financing.
  • BVS has a worse Debt to Equity ratio (1.93) than 81.52% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.93
Debt/FCF 6.22
Altman-Z 1.34
ROIC/WACC0.61
WACC10.92%
BVS Yearly LT Debt VS Equity VS FCFBVS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 1.74 indicates that BVS should not have too much problems paying its short term obligations.
  • With a Current ratio value of 1.74, BVS is not doing good in the industry: 67.93% of the companies in the same industry are doing better.
  • BVS has a Quick Ratio of 1.14. This is a normal value and indicates that BVS is financially healthy and should not expect problems in meeting its short term obligations.
  • BVS has a Quick ratio of 1.14. This is in the lower half of the industry: BVS underperforms 71.74% of its industry peers.
Industry RankSector Rank
Current Ratio 1.74
Quick Ratio 1.14
BVS Yearly Current Assets VS Current LiabilitesBVS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 51.28% over the past year.
  • Measured over the past years, BVS shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -16.93% on average per year.
  • The Revenue has been growing slightly by 1.58% in the past year.
  • BVS shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.01% yearly.
EPS 1Y (TTM)51.28%
EPS 3Y-16.93%
EPS 5YN/A
EPS Q2Q%150%
Revenue 1Y (TTM)1.58%
Revenue growth 3Y9.98%
Revenue growth 5Y11.01%
Sales Q2Q%-0.23%

3.2 Future

  • The Earnings Per Share is expected to grow by 17.45% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 5.25% on average over the next years.
EPS Next Y41.83%
EPS Next 2Y30.71%
EPS Next 3Y25.05%
EPS Next 5Y17.45%
Revenue Next Year0.15%
Revenue Next 2Y3.42%
Revenue Next 3Y4.42%
Revenue Next 5Y5.25%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BVS Yearly Revenue VS EstimatesBVS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2029 2030 200M 400M 600M
BVS Yearly EPS VS EstimatesBVS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2029 2030 0 0.5 1 1.5

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 14.88, the valuation of BVS can be described as correct.
  • Based on the Price/Earnings ratio, BVS is valued cheaply inside the industry as 89.13% of the companies are valued more expensively.
  • BVS's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.07.
  • With a Price/Forward Earnings ratio of 10.93, the valuation of BVS can be described as very reasonable.
  • BVS's Price/Forward Earnings ratio is rather cheap when compared to the industry. BVS is cheaper than 94.57% of the companies in the same industry.
  • BVS's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.05.
Industry RankSector Rank
PE 14.88
Fwd PE 10.93
BVS Price Earnings VS Forward Price EarningsBVS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 91.30% of the companies in the same industry are more expensive than BVS, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, BVS is valued cheaper than 97.28% of the companies in the same industry.
Industry RankSector Rank
P/FCF 13.59
EV/EBITDA 10.94
BVS Per share dataBVS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as BVS's earnings are expected to grow with 25.05% in the coming years.
PEG (NY)0.36
PEG (5Y)N/A
EPS Next 2Y30.71%
EPS Next 3Y25.05%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for BVS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIOVENTUS INC - A

NASDAQ:BVS (2/27/2026, 8:00:02 PM)

After market: 8.78 0 (0%)

8.78

-0.08 (-0.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-04
Earnings (Next)03-05
Inst Owners74.45%
Inst Owner Change2.28%
Ins Owners2.5%
Ins Owner Change0.55%
Market Cap726.63M
Revenue(TTM)563.83M
Net Income(TTM)7.82M
Analysts80
Price Target14.79 (68.45%)
Short Float %2.62%
Short Ratio5.76
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.08%
Min EPS beat(2)-0.99%
Max EPS beat(2)29.14%
EPS beat(4)3
Avg EPS beat(4)86.47%
Min EPS beat(4)-0.99%
Max EPS beat(4)239.51%
EPS beat(8)7
Avg EPS beat(8)133.13%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.3%
Min Revenue beat(2)-0.67%
Max Revenue beat(2)0.07%
Revenue beat(4)2
Avg Revenue beat(4)1.04%
Min Revenue beat(4)-0.67%
Max Revenue beat(4)4.79%
Revenue beat(8)6
Avg Revenue beat(8)4.08%
Revenue beat(12)9
Avg Revenue beat(12)2.76%
Revenue beat(16)10
Avg Revenue beat(16)1.33%
PT rev (1m)-3.33%
PT rev (3m)-3.33%
EPS NQ rev (1m)0.78%
EPS NQ rev (3m)0.78%
EPS NY rev (1m)0%
EPS NY rev (3m)3.13%
Revenue NQ rev (1m)-0.46%
Revenue NQ rev (3m)-0.46%
Revenue NY rev (1m)-0.17%
Revenue NY rev (3m)-0.16%
Valuation
Industry RankSector Rank
PE 14.88
Fwd PE 10.93
P/S 1.29
P/FCF 13.59
P/OCF 12.97
P/B 4.37
P/tB N/A
EV/EBITDA 10.94
EPS(TTM)0.59
EY6.72%
EPS(NY)0.8
Fwd EY9.15%
FCF(TTM)0.65
FCFY7.36%
OCF(TTM)0.68
OCFY7.71%
SpS6.81
BVpS2.01
TBVpS-2.64
PEG (NY)0.36
PEG (5Y)N/A
Graham Number5.16
Profitability
Industry RankSector Rank
ROA 1.11%
ROE 4.71%
ROCE 8.38%
ROIC 6.62%
ROICexc 7.18%
ROICexgc 31.69%
OM 8.03%
PM (TTM) 1.39%
GM 67.76%
FCFM 9.48%
ROA(3y)-11.81%
ROA(5y)-6.59%
ROE(3y)-54.27%
ROE(5y)-31.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y44.62%
ROICexgc growth 5Y-8.7%
ROICexc growth 3Y36.86%
ROICexc growth 5Y-12.41%
OM growth 3Y-2.88%
OM growth 5Y-14.52%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.21%
GM growth 5Y-1.56%
F-Score8
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity 1.93
Debt/FCF 6.22
Debt/EBITDA 3.44
Cap/Depr 5.36%
Cap/Sales 0.45%
Interest Coverage 250
Cash Conversion 60.26%
Profit Quality 683.69%
Current Ratio 1.74
Quick Ratio 1.14
Altman-Z 1.34
F-Score8
WACC10.92%
ROIC/WACC0.61
Cap/Depr(3y)9.96%
Cap/Depr(5y)13.06%
Cap/Sales(3y)1.19%
Cap/Sales(5y)1.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.28%
EPS 3Y-16.93%
EPS 5YN/A
EPS Q2Q%150%
EPS Next Y41.83%
EPS Next 2Y30.71%
EPS Next 3Y25.05%
EPS Next 5Y17.45%
Revenue 1Y (TTM)1.58%
Revenue growth 3Y9.98%
Revenue growth 5Y11.01%
Sales Q2Q%-0.23%
Revenue Next Year0.15%
Revenue Next 2Y3.42%
Revenue Next 3Y4.42%
Revenue Next 5Y5.25%
EBIT growth 1Y178.93%
EBIT growth 3Y6.82%
EBIT growth 5Y-5.11%
EBIT Next Year16.93%
EBIT Next 3Y12.11%
EBIT Next 5Y10.4%
FCF growth 1Y29806.1%
FCF growth 3Y34.24%
FCF growth 5Y-0.3%
OCF growth 1Y448.75%
OCF growth 3Y19.05%
OCF growth 5Y-0.96%

BIOVENTUS INC - A / BVS FAQ

Can you provide the ChartMill fundamental rating for BIOVENTUS INC - A?

ChartMill assigns a fundamental rating of 4 / 10 to BVS.


What is the valuation status for BVS stock?

ChartMill assigns a valuation rating of 8 / 10 to BIOVENTUS INC - A (BVS). This can be considered as Undervalued.


Can you provide the profitability details for BIOVENTUS INC - A?

BIOVENTUS INC - A (BVS) has a profitability rating of 4 / 10.


What is the valuation of BIOVENTUS INC - A based on its PE and PB ratios?

The Price/Earnings (PE) ratio for BIOVENTUS INC - A (BVS) is 14.88 and the Price/Book (PB) ratio is 4.37.


What is the financial health of BIOVENTUS INC - A (BVS) stock?

The financial health rating of BIOVENTUS INC - A (BVS) is 3 / 10.